You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
5-HT2A and 2C receptor antagonist (pA2 values are 9.1 for each receptor) and D2-like dopamine receptor partial agonist (Ki = 8 nM). Displays antiprolactin and antiparkinsonian effects in vivo.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||1.99||5 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 398.95. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.51 mL||12.53 mL||25.07 mL|
|5 mM||0.5 mL||2.51 mL||5.01 mL|
|10 mM||0.25 mL||1.25 mL||2.51 mL|
|50 mM||0.05 mL||0.25 mL||0.5 mL|
References are publications that support the biological activity of the product.
Hoyer et al (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 46 157 PMID: 7938165
Marko (1984) DA agonistic potency of two novel prolactin release-inhibiting ergolines. Eur.J.Pharmacol. 101 263 PMID: 6468500
Markstei (1983) Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1- and D2-receptors. Eur.J.Pharmacol. 95 101 PMID: 6230246
If you know of a relevant reference for Mesulergine hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Mesulergine hydrochloride, Mesulergine hydrochloride supplier, 5-HT2A, 5-HT2C, 5-HT, serotonin, antagonists, D2, dopamine, partial, agonists, antiprolactin, antiParkinsonian, CU-32-085, Receptors, Non-selective, Dopamine, 1644, Tocris Bioscience
2 Citations for Mesulergine hydrochloride
Citations are publications that use Tocris products. Selected citations for Mesulergine hydrochloride include:
Moutkine et al (2017) Heterodimers of serotonin receptor subtypes 2 are driven by 5-HT2C protomers. J Biol Chem 292 6352 PMID: 28258217
Chan et al (2015) Ergot Alkaloids (Re)generate New Leads as Antiparasitics. Neurotoxicology 9 e0004063 PMID: 26367744
Do you know of a great paper that uses Mesulergine hydrochloride from Tocris? Please let us know.
Reviews for Mesulergine hydrochloride
There are currently no reviews for this product. Be the first to review Mesulergine hydrochloride and earn rewards!
Have you used Mesulergine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.